The “Dementia with Diabetes – Pipeline Insight, 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
The “Dementia with Diabetes – Pipeline Insight, 2020,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Dementia with Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Dementia with Diabetes: Overview
Diabetes can cause several complications, such as damage to blood vessels. Diabetes is considered a risk factor for vascular dementia. This type of dementia occurs due to brain damage that is often caused by reduced or blocked blood flow to brain. Many people with diabetes have brain changes that are hallmarks of both Alzheimer’s disease and vascular dementia. Some researchers think that each condition fuels the damage caused by the other.
There’s a lot of research suggesting a connection between diabetes and Alzheimer’s-though those connections aren’t yet fully understood. Not all studies confirm the connection, but many do suggest that people with diabetes, especially type 2 diabetes, are at higher risk of eventually developing Alzheimer’s dementia or other dementias. Diabetes may also increase the risk of developing mild cognitive impairment (MCI), a condition in which people experience more thinking (cognitive) and memory problems than are usually present in normal aging.
Insulin in the Brain
The sensitivity of target cells in the periphery and in the central nervous system (CNS) to insulin, a peptide hormone secreted by pancreatic ?-cells, is suppressed in type 2 diabetes. The CNS is rich with insulin receptors, most prominently in areas important for learning and memory, including the hippocampus, amygdala, parahippocampal gyrus, thalamus, and caudate-putamen.
Role of Insulin in Learning and Memory
A number of studies support insulin as an important factor in normal memory functioning. Potential mechanisms for the influence of insulin on memory include regional effects of insulin on cerebral glucose metabolism, influence on components of the long-term potentiation cascade, and modulation of acetylcholine and norepinephrine, neurotransmitters that are known to influence cognitive function.
Currently, there are different classes of orally available pharmacological agents to treat Type II diabetes: 1) sulfonylureas, 2) meglitinides, 3) metformin (a biguanide), 4) thiazolidinediones (TZDs), 5) alpha glucosidase inhibitors, 6) dipeptidyl peptidase IV (DPP-4) inhibitors, 7) bile acid sequestrants, 8) dopamine agonists, and 9) sodium-glucose transport protein 2 (SGLT2) inhibitors. The treatment regimen for Dementia with Diabetes includes non-insulin therapy (Metformin, Thiazolidinedione, Sulfonylureas Meglitinides, Dipeptidyl peptidase-4 inhibitors and Sodium-glucose cotransporter-2 (SGLT-2)), and insulin therapy.
Dementia with Diabetes Emerging Drugs Chapters
This segment of the Dementia with Diabetes report encloses its detailed analysis of various drugs in the different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Dementia with Diabetes Emerging Drugs
Azeliragon (TTP488): vTv Therapeutics
Azeliragon (TTP488) is developed by vTv Therapeutics which is currently in phase II/III clinical developmental trial in patients with mild- Alzheimer’s disease in patients with type 2 diabetes. Azeliragon (TTP488) is an orally bioavailable small molecule that inhibits the receptor for advanced glycation endproduct (RAGE) being developed for dementia. RAGE is an immunoglobulin-like cell surface receptor that is overexpressed in brain tissues of patients with Alzheimer’s disease. vTv Therapeutics has also received fast-track designation from the US FDA for Azeliragon in Alzheimer’s disease.
Dementia with Diabetes: Therapeutic Assessment
This segment of the report provides insights about the different Dementia with Diabetes drugs segregated based on the following parameters that define the scope of the report, such as:
Major Players in Dementia with Diabetes
There are approx. 5+ key companies which are developing the rapies for Dementia with Diabetes. The companies which have their Dementia with Diabetes drug candidates in the advanced stage, i.e. phase III and include, vTv Therapeutics etc.
This report covers around 5+ products under different phases of clinical development like
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Dementia with Diabetes pipeline report provides therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Proteins and Peptides
- Small molecules
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Dementia with Diabetes: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dementia with Diabetes therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dementia with Diabetes drugs.
- The companies and academics are working to assess challenges and seek opportunities that could influence Dementia with Diabetes R&D. the rapies under development are focused on novel approaches to treat/improve Dementia with Diabetes.
- Currently, several trials with anti-diabetic drugs in the AD are underway and their results are expected in the next few years. Besides, further studies exploring the molecular mechanisms underlying the favorable effects of anti-diabetic drugs in the CNS could open new perspectives on future treatments.
Dementia with Diabetes Report Insights
- Dementia with Diabetes Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Dementia with Diabetes Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Dementia with Diabetes drugs?
- How many Dementia with Diabetes drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dementia with Diabetes?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Dementia with Diabetes therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Dementia with Diabetes and their status?
- What are the key designations that have been granted to the emerging drugs?
- vTv Therapeutics
- Azeliragon (TTP488)
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/je5396
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900